EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSDNOG00000037290
Gene Symbol: DHCR24
4 Cross references
209 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSDNOG00000006472
Gene Symbol: HMGCR
2 Cross references
272 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSDNOG00000023741
Gene Symbol: PDPK1
4 Cross references
244 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSDNOG00000007259
Gene Symbol: HPD
4 Cross references
207 Possible Orthologues:

40s Ribosomal Protein S12-Like

Ensembl ID : ENSDNOG00000034691
Gene Symbol: LOC105745609
3 Cross references
125 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSDNOG00000049197
Gene Symbol: LOC101412757
3 Cross references
249 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSDNOG00000009246
Gene Symbol: HTR1B
4 Cross references
244 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSDNOG00000047574
Gene Symbol: HTR1E
4 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSDNOG00000048869
Gene Symbol: HTR1F
2 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSDNOG00000008954
Gene Symbol: HTR2A
2 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSDNOG00000035356
Gene Symbol: HTR2B
2 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSDNOG00000012807
Gene Symbol: HTR3A
4 Cross references
207 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).